Table 2. The potentially druggable targets and prioritized drugs identified for CCA treatment using PanDrugs software.
| Gene(s) | Show Drug Name | Status Description | Therapy | Drug response | Best Interaction |
|---|---|---|---|---|---|
| RRM2 | CLADRIBINE | Approved for blood cancer | CHEMOTHERAPY | SENSITIVITY | direct-target |
| RRM2 | CLOFARABINE | Approved for blood cancer | CHEMOTHERAPY | SENSITIVITY | biomarker |
| RRM2 | HYDROXYUREA | Approved for blood cancer | CHEMOTHERAPY | SENSITIVITY | biomarker |
| EZH2 | DABRAFENIB | Approved for skin cancer | TARGETED_THERAPY | SENSITIVITY | biomarker |
| RRM2 | FLUDARABINE | Approved for blood cancer | CHEMOTHERAPY | SENSITIVITY | biomarker |
| RRM2 | FLUDARABINE PHOSPHATE | Approved for blood cancer | CHEMOTHERAPY | SENSITIVITY | biomarker |
| CDC20—CDKN3 | AT7519 | Clinical Trials | – | SENSITIVITY | pathway-member |
| RRM2 | MOTEXAFIN GADOLINIUM | Clinical Trials | – | SENSITIVITY | direct-target |
| RRM2 | IMEXON | Clinical Trials | – | SENSITIVITY | direct-target |
| CDC20 | DINACICLIB | Clinical Trials | – | SENSITIVITY | pathway-member |
| CDC20 | FLAVOPIRIDOL | Clinical Trials | – | SENSITIVITY | pathway-member |
| CDC20 | BAY1000394 | Clinical Trials | – | SENSITIVITY | pathway-member |
| CCNB1—EZH2 | SELUMETINIB | Clinical Trials | – | BOTH? | biomarker |
| EZH2 | 1032350 − 13 − 2 | Clinical Trials | – | SENSITIVITY | biomarker |
| RRM2 | TRIAPINE | Clinical Trials | – | SENSITIVITY | biomarker |
| CDKN3 | 602306 − 29 − 6 | Clinical Trials | – | SENSITIVITY | biomarker |
| CDKN3 | PHA-793887 | Clinical Trials | – | SENSITIVITY | biomarker |
| CDKN3 | RONICICLIB | Clinical Trials | – | SENSITIVITY | biomarker |
| HMMR | HYALURONIC ACID | Clinical Trials | – | SENSITIVITY | direct-target |
| CDC20 | ALSTERPAULLONE | Experimental | – | SENSITIVITY | pathway-member |
| CDC20 | HYMENIALDISINE | Experimental | – | SENSITIVITY | pathway-member |
| CDC20 | INDIRUBIN-3′-MONOXIME | Experimental | – | SENSITIVITY | pathway-member |
| CDC20 | OLOMOUCINE | Experimental | – | SENSITIVITY | pathway-member |
| CDC20 | SU9516 | Experimental | – | SENSITIVITY | pathway-member |
| EZH2 | A-395 | Experimental | – | SENSITIVITY | biomarker |
| EZH2 | GSK126 | Experimental | – | SENSITIVITY | biomarker |
| RRM2 | TEZACITABINE | Experimental | – | SENSITIVITY | biomarker |
| FANCI | LY2183240 | Experimental | – | SENSITIVITY | biomarker |
| FANCI | SB 225002 | Experimental | – | SENSITIVITY | biomarker |